Elevance Health Inc

Elevance Health Inc(ELV)の株式分析

$428.260

-0.171 (-0.04%)終値時点

Loading chart…
高値
434.000
始値
433.340
出来高加重平均価格
429.66
出来高
1.22M
時価総額
124.52B
安値
426.720
売買代金
524.23M
EV/EBITDA(TTM)
10.68

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.

www.elevancehealth.com

AI分析 of Elevance Health Inc (ELV)

買い

Elevance Health Inc is a strong buy at the current price of $428.26, supported by a forward P/E ratio of 13.68, indicating potential for growth compared to its earnings. The RSI is at 82.08, suggesting the stock is currently overbought, but this momentum can continue in the short term. The company has shown a robust year-to-date change of +20.89%, reflecting strong performance. However, a risk to consider is the hedge fund selling activity, which has increased by 135.25% over the last quarter, indicating some caution among institutional investors.

バリュエーション指標

Elevance Health Inc(ELV)の現在の予想PERは13.68で、5年平均は13.76です。

予想PER

適正
5年平均 P/E
13.76
現在のP/E
13.68
割高
15.58
割安
11.94

予想EV/EBITDA

適正
5年平均 EV/EBITDA
10.29
現在のEV/EBITDA
10.68
割高
11.86
割安
8.73

予想PSR

適正
5年平均 P/S
0.58
現在のP/S
0.46
割高
0.72
割安
0.44

Alphio AI による ELV の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%ELV

$456.04

シナリオ価格

基

基本

基本 · 50%ELV

$450.58

シナリオ価格

弱

弱気

弱気 · 25%ELV

$379.11

シナリオ価格

ELV を保有するクジラ

A

ARGA Investment Management, LLC

+ を保有ELV

+12.47%

3か月リターン

H

Hotchkis and Wiley Capital Management, LLC

+ を保有ELV

+9.19%

3か月リターン

Y

Yacktman Asset Management LP

+ を保有ELV

+7.03%

3か月リターン

G

Grantham Mayo Van Otterloo & Co. LLC

+ を保有ELV

+6.63%

3か月リターン

L

Lakewood Capital Management, LP

+ を保有ELV

+6.37%

3か月リターン

Y

Y-Intercept (Hong Kong) Limited

+ を保有ELV

+5.48%

3か月リターン

ELV のよくある質問 — Alphio AI が回答

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Elevance Health Inc is a strong buy at the current price of $428.26, supported by a forward P/E ratio of 13.68, indicating potential for growth compared to its earnings. The RSI is at 82.08, suggesting the stock is currently overbought, but this momentum can continue in the short term. The company has shown a robust year-to-date change of +20.89%, reflecting strong performance. However, a risk to consider is the hedge fund selling activity, which has increased by 135.25% over the last quarter, indicating some caution among institutional investors.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める